A critical appraisal of the harm reduction argument for heat-not-burn tobacco products.

Klicks: 419
ID: 89572
2018
Artikelqualität & Leistungskennzahlen
Gesamtqualität
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
KI-Qualitätsbewertung
Nicht analysiert
Readership in this journal
Steady

Ranked #7 of 34 articles by views in revista panamericana de salud publica = pan american journal of public health

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Heat-not-burn products (HNBs) are efficient nicotine delivery devices that heat tobacco instead of burning it, as conventional cigarettes do. Since heating yields less carbon monoxide and other tobacco pyrolysis-derived toxicants, tobacco companies claim that HNBs are less harmful than conventional cigarettes are. Although this hypothesis is plausible, no long-term clinical trials and/or observational studies are available to corroborate it. To overcome barriers to the entry of tobacco products to the market, manufacturers of HNBs argue that they are a new wave of harm reduction alternatives. Nonetheless, even if HNBs were in fact less harmful than conventional cigarettes, they would still have the potential to cause nicotine addiction (a major health hazard) and other harms to smokers' health. HNBs deliver nicotine, provide users a tobacco aroma and flavor and some rituals of smoking, and are supposedly safer than conventional cigarettes. Owing to these features, HNBs are likely to enhance smoking appeal and initiation among young persons and discourage smokers' attempts to quit. In other words, if HNBs were freely available on the market, they would increase the prevalence of smoking. However, HNBs may constitute a harm reduction alternative for nicotine-dependent smokers who are unable or unwilling to quit smoking. Given these facts, approval of HNBs for use under medical supervision (prescription only), along with strict restrictions on advertising, is a balanced regulatory option that would reconcile the therapeutic needs of nicotine-addicted patients with the public heath goal of achieving a smoke-free generation in the near future.
Referenzschlüssel
paumgartten2018arevista Verwenden Sie diesen Schlüssel zum automatischen Zitieren im Manuskript bei Verwendung von SciMatic Manuscript Manager oder Thesis Manager
Autoren Paumgartten, Francisco J R;
Zeitschrift revista panamericana de salud publica = pan american journal of public health
Jahr 2018
DOI
10.26633/RPSP.2018.161
URL
Schlüsselwörter
smoking neoplasms harm reduction nicotine tobacco use disorder

Zitationen

Keine Zitationen gefunden. Um eine Zitation hinzuzufügen, kontaktieren Sie den Administrator unter info@scimatic.org

Kommentare

Noch keine Kommentare. Seien Sie der Erste, der diesen Artikel kommentiert.